Common Antibiotics Linked to Life-Changing Psychiatric Effects
- The Therapeutic Goods Administration (TGA) has issued an alert concerning the use of broad-spectrum antibiotics, frequently prescribed for infections affecting the urinary tract, respiratory system, and gastrointestinal system.
- The alert focuses on antimicrobials belonging to the broad-spectrum fluoroquinolone class of antibiotics.
- The primary concern revolves around adverse effects on the central nervous system (CNS) and potential psychiatric events.
Fluoroquinolone Antibiotics: TGA Issues Alert Over Potential Psychiatric Effects
Table of Contents
- Fluoroquinolone Antibiotics: TGA Issues Alert Over Potential Psychiatric Effects
- Fluoroquinolone Antibiotics: What You Need to Know About the TGA Alert
- What are Fluoroquinolone Antibiotics?
- Which antibiotics are included in the TGA alert?
- What is the TGA’s primary concern regarding fluoroquinolones?
- What are the documented adverse effects associated with fluoroquinolones?
- What kind of psychiatric reactions can fluoroquinolones cause?
- What is being done to address the risks associated with fluoroquinolones?
- Why are these changes necessary?
- What should patients do if they experience adverse effects while taking fluoroquinolones?
- What are the recommendations for pharmacists regarding fluoroquinolone prescriptions?
- How prevalent are fluoroquinolone prescriptions?
- What is tendonitis and tendon rupture, and how are they related to fluoroquinolones?
- What alternatives are available if fluoroquinolones are not suitable?
- Fluoroquinolone Antibiotics: Key Information at a Glance
- Disclaimer
Posted on:
The Therapeutic Goods Administration (TGA) has issued an alert concerning the use of broad-spectrum antibiotics, frequently prescribed for infections affecting the urinary tract, respiratory system, and gastrointestinal system.
Which Antibiotics Triggered the alert?
The alert focuses on antimicrobials belonging to the broad-spectrum fluoroquinolone class of antibiotics. This includes drugs like ciprofloxacin, norfloxacin, and moxifloxacin. The warning applies to all forms of fluoroquinolones, weather administered orally or via injection.
Documented adverse Effects of Fluoroquinolones
The primary concern revolves around adverse effects on the central nervous system (CNS) and potential psychiatric events. While these complications are rare, the TGA emphasizes that they are serious and can be “perhaps disabling and irreversible.”
Specific adverse events include:
- Tremors, restlessness, light-headedness
- Hallucinations or seizures (very rarely)
- Tendonitis and tendon ruptures
- Psychiatric reactions, including confusion, anxiety, and depression
These adverse effects can manifest in patients without any pre-existing risk factors. A particularly concerning case involved “the suicide of a respected UK-based consultant cardiologist” who died shortly after starting ciprofloxacin treatment. The coroner highlighted that the doctor, in a letter, expressed “uncharacteristically confused and illogical’ worries.”
What changes Are Being Implemented?
Updates will be made to the Product Information (PI) and Consumer Medicine Information (CMI) for all oral and injectable fluoroquinolones. These updates aim to enhance awareness among both healthcare professionals and patients regarding the potential for severe adverse effects.
For instance, the boxed warning for ciprofloxacin will now explicitly state:
Serious disabling and potentially irreversible adverse reactions
The warning continues:
Fluoroquinolones, including ciprofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions involving different body systems that have occurred together in the same patient. Patients of any age or without pre-existing risk factors have experienced these adverse reactions.These include but are not limited to serious adverse reactions involving the nervous system (see section 4.4 Effects on the CNS),musculoskeletal system (see section 4.4 Tendonitis and tendon rupture) and psychiatric effects (see section 4.4 psychiatric reactions).
Why Are These Changes Necessary?
In 2023, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) conducted an examination into severe adverse effects linked to fluoroquinolones. The review resolute that previous measures implemented in 2019, which aimed to restrict prescriptions for minor or non-bacterial illnesses, had not substantially reduced usage rates. Consequently, the MHRA recommended strengthening safety warnings and directly informing healthcare providers about the associated risks.
Following this review, prominent “boxed warnings” will be incorporated into Australian PI and CMI documents to clearly communicate these serious adverse effects, aligning with international regulatory guidance.
Recommendations for Pharmacists
Fluoroquinolones should be reserved for patients who have no other viable treatment options. Pharmacists are urged to ensure that these antibiotics are prescribed judiciously and in accordance with established antibiotic guidelines.
When dispensing fluoroquinolones like ciprofloxacin,norfloxacin,and moxifloxacin,pharmacists should counsel patients to be vigilant for any unusual symptoms following the start of treatment. Patients should be advised to seek immediate medical attention if they experience any adverse reactions, and fluoroquinolone treatment should be promptly discontinued.
Fluoroquinolone Antibiotics: What You Need to Know About the TGA Alert
The Therapeutic goods Governance (TGA) has recently issued an alert regarding fluoroquinolone antibiotics due to potential psychiatric and other serious adverse effects. This Q&A provides a comprehensive overview of this alert, what it means for you, and what actions are being taken to improve patient safety.
What are Fluoroquinolone Antibiotics?
Fluoroquinolones are a class of broad-spectrum antibiotics used to treat various bacterial infections.
Which antibiotics are included in the TGA alert?
The TGA alert specifically addresses fluoroquinolone antibiotics, including drugs such as:
Ciprofloxacin
Norfloxacin
Moxifloxacin
This warning applies to all forms of these medications, whether administered orally or via injection.
What is the TGA’s primary concern regarding fluoroquinolones?
The primary concern is the potential for severe adverse effects on the central nervous system (CNS) and the occurrence of psychiatric events. While these complications are rare, the TGA emphasizes that they can be serious, perhaps disabling, and irreversible.
What are the documented adverse effects associated with fluoroquinolones?
The documented adverse effects include:
tremors, restlessness, and light-headedness
Hallucinations or seizures (very rarely)
Tendonitis and tendon ruptures
Psychiatric reactions, including confusion, anxiety, and depression
These effects can occur in patients without any pre-existing risk factors.
What kind of psychiatric reactions can fluoroquinolones cause?
fluoroquinolones have been linked to several psychiatric reactions,including:
Confusion
Anxiety
Depression
Hallucinations (rare)
What is being done to address the risks associated with fluoroquinolones?
The TGA is implementing the following changes:
Updates to Product Data (PI) and Consumer Medicine Information (CMI): These updates aim to enhance awareness among healthcare professionals and patients regarding the potential for severe adverse effects.
Boxed warnings: Prominent boxed warnings will be added to Australian PI and CMI documents to clearly communicate these serious adverse effects. For example, the boxed warning for ciprofloxacin will now explicitly state: ”Serious disabling and potentially irreversible adverse reactions.”
Why are these changes necessary?
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) found that previous measures to restrict prescriptions for minor or non-bacterial illnesses had not substantially reduced usage rates. As an inevitable result,the MHRA recommended strengthening safety warnings and directly informing healthcare providers about the associated risks,leading to the implementation of boxed warnings in Australia.
What should patients do if they experience adverse effects while taking fluoroquinolones?
Patients should seek immediate medical attention if they experience any unusual symptoms following the start of treatment with fluoroquinolones. It is indeed also crucial to discontinue fluoroquinolone treatment promptly if any adverse reactions occur.
What are the recommendations for pharmacists regarding fluoroquinolone prescriptions?
Pharmacists are urged to ensure that fluoroquinolones are prescribed judiciously and in accordance with established antibiotic guidelines. They should be reserved for patients who have no other viable treatment options.when dispensing fluoroquinolones, pharmacists should counsel patients to be vigilant for any unusual symptoms following the start of treatment.
How prevalent are fluoroquinolone prescriptions?
While the exact figures for Australia aren’t provided in the article, the MHRA review in the UK indicated that previous restrictions had not significantly reduced usage rates. This underscores the need for stronger warnings and greater awareness among healthcare providers and patients.
Tendonitis is the inflammation of a tendon, while a tendon rupture is a tear in the tendon. Fluoroquinolones have been associated with an increased risk of these musculoskeletal issues, particularly affecting the Achilles tendon. The exact mechanism is not fully understood but is believed to involve changes in tendon structure and function caused by the drug.
What alternatives are available if fluoroquinolones are not suitable?
The appropriate alternative antibiotic will depend on the type of infection being treated. Your doctor will consider factors such as the specific bacteria causing the infection, your medical history, and any allergies you may have.Common alternatives include:
Beta-lactam antibiotics: Such as penicillins and cephalosporins.
Macrolides: Such as erythromycin and azithromycin.
Tetracyclines: Such as doxycycline.
Sulfonamides: Such as trimethoprim-sulfamethoxazole.
Fluoroquinolone Antibiotics: Key Information at a Glance
| Feature | Description |
| ——————— | —————————————————————————————————————————————————————————————————————————————— |
| class | Broad-spectrum antibiotics |
| Examples | Ciprofloxacin, Norfloxacin, Moxifloxacin |
| TGA Alert | Issued due to potential psychiatric and CNS adverse effects |
| Adverse Effects | Tremors, restlessness, hallucinations, seizures (rare), tendonitis, tendon ruptures, confusion, anxiety, depression |
| Actionable Advice | Reserved for cases with no alternative treatment options. Patients should seek immediate medical attention for unusual symptoms and discontinue use if adverse effects occur. Pharmacists should dispense judiciously and counsel patients. |
| Regulatory Change | Enhanced warnings in Product Information (PI) and Consumer Medicine Information (CMI) |
Disclaimer
This Q&A provides general information regarding the TGA alert on fluoroquinolone antibiotics and should be used for informational purposes only,this article is not a substitute for professional medical advice. Always consult with a healthcare professional for diagnosis and treatment.*